Head of the Graduate School at St George's, University of London.
President of the Israel Academy of Sciences & Humanities. Former VP of the Weizmann Institute of Science. Significant contributions to vaccine development, cancer research & parasitic diseases. Has served as President of EFIS and Secretary-General of the IUIS. Awards include the Robert Koch Prize in Medical Sciences, Spain’s Diaz Memorial Prize, France's Legion of Honor, the Hadassah World Organization's Women of Distinction Award, the Wolf Prize for Medicine, the Rothschild Prize for Biology.
Professor of Immunology and Basic Oncology; Center for Molecular Medicine and Stem Cells Research, Faculty of Medical Sciences, University of Kragujevac.
I am a professor of Microbiology and Immunology at Faculty of Pharmacy, Cairo University, Egypt. I am interested in microbiome research, pharmacomicrobiomics, evolution and emergence microbial pathogenesis and resistance, microbial and phage genomics, antibiotic resistance surveillance, adaptive laboratory evolution, metabolic reconstruction and pathway gap filling, and virulence gene discovery.
Professor of Thoracic Medicine at the National Heart and Lung Institute, Head of Respiratory Medicine at Imperial College & Honorary Consultant Physician at Royal Brompton Hospital, London. Has been the most highly cited clinical scientist in Europe & the most highly cited respiratory researcher in the world over the last 20 years. Elected a Fellow of the Royal Society in 2007. Currently a member of the Scientific Committee of the WHO/NIH global guidelines on asthma (GINA) and COPD (GOLD).
Barnes is the author of over 1,000 publications in peer reviewed journals. He has edited or co-edited over 50 books on asthma, COPD and respiratory pharmacology.
He has been received honorary degrees from the Universities of Ferrara (Italy), Athens (Greece), Tampere (Finland), Leuven (Belgium) and Maastricht (Netherlands). He co-founded an Imperial spin-out company RespiVert, which was acquired by Johnson & Johnson and has developed novel inhaled treatments for COPD and severe asthma.
Jürgen C. Becker is Professor of Dermatology at the Meduni Graz, Austria. He received his MD from the Medical School Hanover and his PhD in Immunology from the Open University, London. His research interests include the characterisation of cellular und humoral immune responses in the setting of neoplastic diseases; genetic and epigenetic aberrations in cancer; as well as therapeutic interventions to treat cancer.
Regental Professor and Director of the Center for the Genetics of Host Defense at the UT Southwestern Medical Center in Dallas, Texas. Member of the National Academy of Sciences and the Institute of Medicine. Recipient of many awards, including the 2011 Nobel Prize for Medicine; the 2011 Shaw Prize; the 2009 Will Rogers Institute Annual Prize; the 2009 Albany Medical Center Prize; the 2007 Balzan Prize and the 2004 Robert Koch Prize. (Photo by Brian Coats for UT Southwestern Med Ctr)
A.W. and Mary Margaret Clausen Distinguished Professor and Director, Hormone Research Institute. Serves on the Science Translational Medicine advisory board and founding Director, Immune Tolerance Network. A recipient of a Guggenheim Fellowship and elected member of the Academy of Arts and Sciences and National Academy of Medicine. Dr. Bluestone has spent over 35 years working as an immunologist interested in immune tolerance as it relates to autoimmunity and organ transplantation.
Obtained her PhD degree in the University of Paris VII in 1993, and trained as a post-doc in Prof. John Dick’s group in Toronto. In 1998, she became Group Leader at the Coriell Institute for Medical Research and Assistant Professor, University of Medicine and Dentistry of New Jersey. In 2001, she joined the London Research Institute. Since 2002, she is also Professor, University College of London and Senior Lecturer at the Institute of Child Health.
Dr. Vincenzo Brancaleone is Assistant Professor of Pharmacology, Department of Science, University of Basilicata.
Dr. Brancaleone main research field includes:
1) vascular biology in vivo and in vitro in physiopathological conditions related to gaseous mediators: role of nitric oxide (NO) and hydrogen sulfide (H2S);
2) role of sphingosine-1-kinase/sphingosine-1-phosphate (S1PK/S1P) pathway in vascular, respiratory and inflammatory processes;
3) role of Annexin A1 and its receptor (Formylated Peptide Receptor 2, FPR2) in resolving mechanism in inflammation.
Dr. Brancaleone is full member of British Pharmacological Society (BPS) and Italian Society of Pharmacology (SIF).
He performs reviewer activity for international relevant and impacted scientific journal: Mediators of Inflammation (IF:3.263), British Journal of Pharmacology (IF:4.409), Inflammation Research (IF:2.109), Diabetes & Vascular Disease Research (IF:2.116), FasebJ (IF:5.299)
Dunja Bruder did her PhD thesis in immunology focussing on T cell responses to bacterial toxins (1996-1999) followed by a postdoc in the field of mucosal immunology at the HZI in Braunschweig (2000-2006). After several scientific stays abroad (Harvard Medical School; Yale University School of Medicine) she became head of the research group “Immune Regulation” at the HZI (2006). In addition, since 2011 Dunja Bruder is Professor for "Infection Immunology" at the University Hospital in Magdeburg.
Alessandra Cambi received a Ph.D in Biology at the University of Camerino (Italy) and a Ph.D in Medical Sciences (cum laude) at the Radboud University Nijmegen (The Netherlands). After a long-term EMBO postdoctoral fellowship at the Max Planck Institute of Biphysical Chemistry (Germany) and a VENI fellowship from the Dutch Scientific Organization (NWO), she became junior group leader. She is currently associate professor and group leader of the Nano-Immunology group in Nijmegen.